ESMO 2017 Highlights in Genitourinary Cancers: Treatment Advances

Speaker: Bernard Escudier, Stephane Oudard

Bernard Escudier explains the results from the practice changing CheckMate 214 study that supports the use of combined nivolumab plus ipilimumab as a potential first-line treatment for patients with intermediate/poor risk metastatic renal cell carcinoma, particularly those patients having tumour PD-L1 expression ≥1%.

Bernard Escudier explains the results from the practice changing CheckMate 214 study that supports the use of combined nivolumab plus ipilimumab as a potential first-line treatment for patients with intermediate/poor risk metastatic renal cell carcinoma, particularly those patients having tumour PD-L1 expression ≥1%.

Stephane Oudard comments on great advances presented during the ESMO 2017 Congress in prostate and bladder cancer.

He said that adding abiraterone to the standard therapy for patients with high risk non-metastatic prostate cancer may become the standard of care (STAMPEDE study).

Claire Vale reports on a meta-analysis from 6 trials exploring what the optimal systemic treatments are in patients with hormone positive metastatic prostate cancer, and shows that AAP is likely to be the optimal treatment in this setting.

Daniel Petrylak presents the results from the RANGE study which addresses whether the addition of an antiangiogenesis agent, ramucirumab, improves PFS in patients treated with docetaxel based chemotherapy with metastatic urothelial adenocarcinoma who have failed one previous platinum based chemotherapy regimen. The combination resulted in nearly doubling the objective response rate with no more toxicity than in the control arm.

 

Abstracts

  • LBA5 - Escudier B, et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups.
  • LBA34 - Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)
  • LBA33 - What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis
  • LBA4_PR - RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

More resources from ESMO 2017 Congress